ArticleCancer cell2021
Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma.
Erratum issuedOpen access · bronzeAbstract read
In one paragraph
Article in Cancer cell, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 409 papers, 3 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
409citing papers in PubMed, 3 pooled it
44.2field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
409 citing papers in PubMed, 3 syntheses or guidelines pooled it, 602 citations in OpenAlex.
- Impact of tumor immunotherapy on kidney injury and multi-organ outcomes: a mechanistic and clinical perspective.Frontiers in immunology · 2026Pooled it
- Impact of time-of-day administration of immunotherapy on survival in metastatic renal cell carcinoma: the MOUSEION-09 meta-analysis.Clinical & experimental metastasis · 2024Pooled it
- Impact of pretreatment body mass index on clinical outcomes in patients with metastatic renal cell carcinoma receiving first-line immune checkpoint inhibitor-based therapy: A systematic review and meta-analysis.Investigative and clinical urology · 2024Pooled it
- Dissecting the Tumor Microenvironment to Identify Biomarkers of Outcome to Anti-PD-1 Therapy in Clear-Cell Renal Cell Carcinoma: Analyses of the HCRN GU16-260 Trial.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Trial
- 4-1BBCell reports. Medicine · 2025Trial
- Immune checkpoint inhibitors plus debulking surgery for patients with metastatic renal cell carcinoma: clinical outcomes and immunological correlates of a prospective pilot trial.Nature communications · 2025Trial
- Integrated Immunological Analysis of Interactions Between CXCL13+ T Cells and LAMP3+ DC in the Immunotherapy Response of Bladder Cancer.Molecular carcinogenesis · 2026Article
- FOXP1 Knockdown Reprograms Th9 CAR-T Cells to Overcome Antigen Escape.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Machine learning and multi-omics clustering to map cellular rewiring and immune evasion in ccRCC.Human genomics · 2026Article
- Renal cell carcinoma: molecular understanding and therapeutic development.Cell death and differentiation · 2026Review
- Reviving cancer vaccines in renal cell carcinoma: a new chapter in immunotherapy for kidney cancer.Immuno-oncology technology · 2026Review
- Deep visual multi-omics profiling links morphology and molecular programs in clear cell renal cell carcinoma.EMBO molecular medicine · 2026Article
- Crosstalk Between CTSBAdvanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Antitumour Effects of β-Blockers: A Narrative Review of the Literature.Current issues in molecular biology · 2026Review
- Integrative multi-omics analysis identifies SMIM24 as a favorable prognostic biomarker in clear cell renal cell carcinoma.Functional & integrative genomics · 2026Article
- SPINK1-driven cellular heterogeneity and interaction networks in intrahepatic cholangiocarcinoma revealed by integrated multi-omics analysis.Journal of advanced research · 2026Article
- Targeting MMA-induced USP36 methylmalonylation to suppress macrophage polarization and tumor progression in clear-cell renal cell carcinoma.Cell death and differentiation · 2026Article
- Multi-omic characterization of 14q deletion in renal clear cell carcinoma identifiesJournal for immunotherapy of cancer · 2026Article
- Predictors of Immune Checkpoint Blockade Response in dMMR Colorectal Cancer Using an Integrated Immune-Enhanced Multiomics Platform.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- Hypoxia shapes both therapeutic response and resistance in metastatic clear cell renal cell carcinoma.Cancer cell · 2026Article
349 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Erratum issued
Authors and funding
30 authors at 4 institutions in 1 country.
Kevin BiDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA; Center for Cancer Genomics, Dana-Farber Cancer Institute, Boston, MA 02115, USA; Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA.
Meng Xiao HeDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA; Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA; Harvard Graduate Program in Biophysics, Boston, MA 02115, USA.
Ziad BakounyDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
Abhay KanodiaDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA; Center for Cancer Genomics, Dana-Farber Cancer Institute, Boston, MA 02115, USA; Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA.
Sara NapolitanoDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA; Center for Cancer Genomics, Dana-Farber Cancer Institute, Boston, MA 02115, USA; Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA.
Jingyi WuDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA; Center for Cancer Genomics, Dana-Farber Cancer Institute, Boston, MA 02115, USA; Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA.
Grace GrimaldiDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA; Center for Cancer Genomics, Dana-Farber Cancer Institute, Boston, MA 02115, USA; Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA.
David A BraunDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA; Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA; Harvard Medical School, Boston, MA 02115, USA.
Michael S CuocoBroad Institute of Harvard and MIT, Cambridge, MA 02142, USA.
Angie MayorgaDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA; Center for Cancer Genomics, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
Laura DelloStrittoDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA; Center for Cancer Genomics, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
Gabrielle BouchardDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
John SteinharterDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
Alok K TewariDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA; Harvard Medical School, Boston, MA 02115, USA.
Natalie I VokesDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA; Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA.
Erin ShannonBroad Institute of Harvard and MIT, Cambridge, MA 02142, USA.
Maxine SunDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
Jihye ParkDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA; Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA.
Steven L ChangDivision of Urology, Brigham and Women's Hospital, Boston, MA 02115, USA.
Bradley A McGregorDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
Rizwan HaqDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA; Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA.
Thomas DenizeHarvard Medical School, Boston, MA 02115, USA; Department of Pathology, Brigham and Women's Hospital, Boston, MA 02115, USA.
Sabina SignorettiHarvard Medical School, Boston, MA 02115, USA; Department of Pathology, Brigham and Women's Hospital, Boston, MA 02115, USA; Department of Oncologic Pathology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
Jennifer L GuerrieroHarvard Medical School, Boston, MA 02115, USA; Breast Tumor Immunology Laboratory, Women's Cancer Program, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Sébastien VigneauDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA; Center for Cancer Genomics, Dana-Farber Cancer Institute, Boston, MA 02115, USA; Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA.
Orit Rozenblatt-RosenBroad Institute of Harvard and MIT, Cambridge, MA 02142, USA.
Asaf RotemDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA; Center for Cancer Genomics, Dana-Farber Cancer Institute, Boston, MA 02115, USA; Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA.
Aviv RegevBroad Institute of Harvard and MIT, Cambridge, MA 02142, USA; Howard Hughes Medical Institute and Koch Institute for Integrative Cancer Research, Department of Biology, MIT, Cambridge, MA 02139, USA.
Toni K ChoueiriDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA; Harvard Medical School, Boston, MA 02115, USA.
Eliezer M Van AllenDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA; Center for Cancer Genomics, Dana-Farber Cancer Institute, Boston, MA 02115, USA; Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA. Electronic address: eliezerm_vanallen@dfci.harvard.edu.
Broad Institute · USDana-Farber Cancer Institute · USBrigham and Women's Hospital · USHarvard University · US
Funding
Treating the P13-Kinase/AKTP50CA101942 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI David McDermott · 2003 to 2026
$53.4MPhysician Scientist Training in Cancer ResearchT32CA009172 · NCI · DANA-FARBER CANCER INSTITUTE · PI Jennifer R Brown, James A. DeCaprio · 1985 to 2026
$17.1MMOLECULAR BIOPHYSICS TRAINING GRANTT32GM008313 · NIGMS · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI MURTHY, VENKATESH N · 1989 to 2023
$14.6MThe Cellular Geography of Therapeutic Resistance in CancerU2CCA233195 · NCI · DANA-FARBER CANCER INST · PI JOHNSON, BRUCE E. · 2018 to 2023
$13.7MMolecular and immune drivers of immunotherapy responsiveness in prostate cancerU01CA233100 · NCI · DANA-FARBER CANCER INST · PI FONG, LAWRENCE, VAN ALLEN, ELIEZER M · 2018 to 2022
$4.2MIntegrative Somatic and Germline Computational Biology to Redefine Clinical Actionability in Solid TumorsR01CA227388 · NCI · DANA-FARBER CANCER INST · PI VAN ALLEN, ELIEZER M · 2018 to 2022
$2.0MNCI NIH HHS P50 CA101942NCI NIH HHS R01 CA227388NCI NIH HHS T32 CA009172NCI NIH HHS U01 CA233100NCI NIH HHS U2C CA233195NIGMS NIH HHS T32 GM008313
Abstract
Immune checkpoint blockade (ICB) results in durable disease control in a subset of patients with advanced renal cell carcinoma (RCC), but mechanisms driving resistance are poorly understood. We characterize the single-cell transcriptomes of cancer and immune cells from metastatic RCC patients before or after ICB exposure. In responders, subsets of cytotoxic T cells express higher levels of co-inhibitory receptors and effector molecules. Macrophages from treated biopsies shift toward pro-inflammatory states in response to an interferon-rich microenvironment but also upregulate immunosuppressive markers. In cancer cells, we identify bifurcation into two subpopulations differing in angiogenic signaling and upregulation of immunosuppressive programs after ICB. Expression signatures for cancer cell subpopulations and immune evasion are associated with PBRM1 mutation and survival in primary and ICB-treated advanced RCC. Our findings demonstrate that ICB remodels the RCC microenvironment and modifies the interplay between cancer and immune cell populations critical for understanding response and resistance to ICB.
Indexed as
ImmunotherapyCarcinoma, Renal CellDNA-Binding ProteinsHumansImmunologic FactorsKidney NeoplasmsTranscription FactorsTumor MicroenvironmentDNA-Binding ProteinsImmunologic FactorsPBRM1 protein, humanTranscription Factorscancerimmunotherapykidneyresistancesingle cell
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.